Modifying the immune response to treat oral cancer
Reprogramming the Tumor-Immune Interface in Oral Cancer
This study is looking at how to boost the immune system's ability to fight oral squamous cell carcinoma (a type of mouth cancer) by understanding how cancer cells and immune cells work together, with the hope of creating better treatments for patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-10852877 on NIH RePORTER |
What this research studies
This research focuses on oral squamous cell carcinoma (OSCC), a serious cancer affecting the mouth's mucosal surfaces. It aims to enhance the body's immune response against tumors by investigating how tumor cells interact with immune cells in the tumor microenvironment. The researchers will analyze primary tumor samples and utilize innovative mouse models to explore factors that influence tumor sensitivity to immune attacks, the expression of neoantigens, and the behavior of immune cells. By understanding these interactions, the goal is to develop more effective immunotherapies for OSCC patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with oral squamous cell carcinoma, particularly those with advanced disease.
Not a fit: Patients with early-stage oral cancer or those with other types of cancers unrelated to OSCC may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved immunotherapy treatments for patients with oral cancer, potentially increasing survival rates.
How similar studies have performed: Previous research has shown promising results in enhancing immune responses in various cancers, indicating potential for success in this novel approach.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Sunwoo, John B — Stanford University
- Study coordinator: Sunwoo, John B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.